<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774228</url>
  </required_header>
  <id_info>
    <org_study_id>ITX-08-002</org_study_id>
    <nct_id>NCT00774228</nct_id>
  </id_info>
  <brief_title>I-ZIP Ocular Bandage Pivotal Study</brief_title>
  <official_title>Clinical Evaluation of the I-ZIP® Ocular Bandage as a Protective Ocular Bandage in Subjects Undergoing Clear Corneal Cataract Surgery With IOL Implantation: A Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and performance of the I-ZIP Ocular Bandage in subjects undergoing&#xD;
      uneventful unilateral clear corneal phacoemulsification with foldable monofocal intraocular&#xD;
      lens (IOL) implantation compared with the Oasis 24-hour Soft Shield Collagen Corneal Shield&#xD;
      (Oasis Medical, Inc. Glendora, California) for providing ocular protection and relief of pain&#xD;
      or discomfort in the acute post-operative period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device remains localized over corneal incision</measure>
    <time_frame>24 hours post operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse ocular events</measure>
    <time_frame>30 days post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>I-ZIP Ocular Bandage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I-Zip bandage application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oasis 24 hour Soft Shield Collagen Corneal Shield</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oasis shield application</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>I-ZIP Ocular Bandage</intervention_name>
    <arm_group_label>I-ZIP Ocular Bandage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oasis 24 Hour Soft Shield Collagen Corneal Shield</intervention_name>
    <arm_group_label>Oasis 24 hour Soft Shield Collagen Corneal Shield</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a cataract and is expected to undergo unilateral clear corneal cataract&#xD;
             surgery with phacoemulsification and implantation of a posterior chamber monofocal&#xD;
             intraocular lens through an incision ≤ 3.5mm in width measured after IOL implantation&#xD;
             using internal calipers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any intraocular inflammation in the study eye that was present during the screening&#xD;
             slit-lamp examination or presence of ocular pain in the operative eye as rated on the&#xD;
             pre-operative NRPS&#xD;
&#xD;
          -  Previous surgery (laser or incisional) or ocular trauma to the operative eye or&#xD;
             planned multiple procedures during cataract/IOL implantation surgery&#xD;
&#xD;
          -  Potential BCVA in fellow eye worse than 20/40 as assessed by the clinical Investigator&#xD;
&#xD;
          -  Active or history of chronic or recurrent inflammatory eye disease (iritis, scleritis,&#xD;
             uveitis, iridocyclitis, rubeosis iritis), evidence of acute external ocular&#xD;
             infections, intraocular infection, dysthyroid ophthalmopathy, nasolacrimal duct&#xD;
             obstruction, active chalazion, uncontrolled blepharitis, uncontrolled and clinically&#xD;
             significant dry eye syndrome, anything more than trace guttata (&gt;10 guttae in the&#xD;
             central 6 mm of cornea), evidence of glaucoma/glaucoma suspect, corneal dystrophy or&#xD;
             other ocular disease that would interfere with study evaluations&#xD;
&#xD;
          -  Subject is currently receiving antineoplastic therapy&#xD;
&#xD;
          -  Use of topical ocular steroids within 14 days and/or systemic steroids (excluding&#xD;
             inhalants) within 30 days prior to surgery.&#xD;
&#xD;
          -  Subject is an insulin-dependent diabetic or has background diabetic retinopathy (BDR),&#xD;
             proliferative diabetic retinopathy (PDR) or compromised macular function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>I-Therapeutix, Inc.</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract or intraocular lens placement surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Product is not commercially available and has been discontinued</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

